Sarepta

News

Young lonely man in a wheelchair on a balcony looking at the nature in the spring

Pfizer pauses Duchenne gene therapy trial after patient deat...

Pfizer has called a halt to a clinical trial of its gene therapy for Duchenne muscular dystrophy as it investigates the unexpected death of a young male patient.

News

Will Gottlieb follow up on Trump's promise of a bonfire of regulations?

Aduhelm approval could signal new era for CNS drugs; analyst...

The unexpected approval and lofty pricing of Biogen's Alzheimer's therapy Aduhelm is clearly the biopharma event of the year so far, but what are the broader implications for the industry a

News

DNA helix in a futuristic concept of the evolution of science and medicine.

First UK patient joins Pfizer's phase 3 DMD gene therapy tri...

The first UK patient has enrolled on Pfizer’s phase 3 trial for its Duchenne muscular dystrophy (DMD) gene therapy.

Events

Partner Content

Gene Therapy for Muscular Disorders

The ONLY digital meeting in this space!

News

Sarepta helps bankroll new gene therapy startup AavantiBio

Sarepta chief commercial officer Bo Cumbo has left to head up gene therapy venture – AavantiBio – with $107 million in backing from his former employer and three high-profile life sciences

News

NS Pharma takes on Sarepta as FDA approves DMD drug

The FDA has approved a new therapy for the rare muscle wasting disease Duchenne muscular dystrophy (DMD) as Japan’s NS Pharma takes on Sarepta and its controversially approved rival.

Pfizer pauses Duchenne gene therapy trial after patient deat...

Aduhelm approval could signal new era for CNS drugs; analyst...

First UK patient joins Pfizer's phase 3 DMD gene therapy tri...

Gene Therapy for Muscular Disorders

Sarepta helps bankroll new gene therapy startup AavantiBio

NS Pharma takes on Sarepta as FDA approves DMD drug

NHS to offer Wegovy to a million more people in England

Using AI-driven synthetic personas to take your insights fur...

Sarepta

Editor's Picks